Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs);Toleranz von coxiben bei intoleranz gegenüber nicht-steroidalen antirheumatika (NSAR)

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 40, 2005, Pages 2249-2252

  Boehncke, S ^a   Boehncke, Wolf Henning ^b  

^a Zentrum der Inneren Medizin   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLEMASTINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; VALDECOXIB;

ADOLESCENT; ADULT; AGED; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; PROVOCATION TEST; SIDE EFFECT; SYMPTOMATOLOGY; URTICARIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; SKIN TESTS; SULFONAMIDES; URTICARIA;

EID: 27144444808     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-918556     Document Type: Article

References (21)

1. Ahlbach S, Usadel KH, Kaufmann R, Boehncke W-H. The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs. Med Klin 2003; 98: 242-244
2. Arzneimittelkommission der deutschen Ärzteschaft. "Aus der UAW-Datenbank" - Kardiovaskuläre Nebenwirkungen sind ein Klasseneffekt aller Coxibe: Konsequnezen für ihre künftige Verordnung. Dtsch Ärztebl 2004; 101: A3365
3. Brune K. Konsequenzen aus der Rücknahme von Rofecoxib. Dtsch Ärztebl 2005; 102: A353-354
4. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and as-pirin intolerance. N Engl J Med 2001; 344: 142
5. Garcia-Rodriguez RM, Hinojosa M, Camacho-Garrido E, Gimeno PB, Garcia M. Celecoxib, safe in NSAID intolerance. Allergy 2002; 57: 1085-1086
6. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: in press
7. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-314
8. Kosnik M, Music E, Matjez F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998; 53: 1231-1233
9. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T, Iscar A. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002; 121: 1812-181
10. Nettis E, di Paola R, Ferrannini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to noinsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 88: 331-334
11. Okie S. Raising the safety bar - the PDA's coxib meeting. New Engl J Med 2005; 352: 1283-1285
12. Pacor ML, di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002; 32: 397-400
13. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 2001; 345: 1856
14. Schrör K. Kardiovaskuläre Risiken von COX-2-Hemmern. Dtsch Med Wochenschr 2004; 129: 2653-2656
15. Stevenson DD. Pathogenesis of aspirin-exacerbated respiratory disease. Vlin Rev Allergy Immunol 2003; 24: 169-188
16. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108: 47-51
17. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31: 219-225
18. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002; 46: 2201-2206
19. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-1899
20. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000; 106: 1201-1202
21. Zollner TM, Ahlbach S, Kaufmann R, Boehncke W-H. Verträglichkeit des selektiven Cyclooxygenase-2-Inhibitors Rofecoxib bei Intoleranz gegenüber nicht-steroidalen Antiphlogistika. Dtsch Med Wschr 2001; 126: 386-388